EC Number   |
Natural Substrates |
|---|
   1.14.14.94 | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
| 1.14.14.94 | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate + [reduced NADPH-hemoprotein reductase] + O2 |
inactivation of leukotriene B4, a mediator of inflammation |
| 1.14.14.94 | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate + [reduced NADPH-hemoprotein reductase] + O2 |
LTB4 inactivation, in vivo inhibition of CYP4F18 results in a marked increase in calcium flux and a 220% increases in the chemotactic response of mouse polymorphonuclear leukocytes to LTB4 |
| 1.14.14.94 | arachidonate + [reduced NADPH-hemoprotein reductase] + O2 |
the enzyme is the principal arachidonate omega-hydroxylase in liver, CYP4F2 |
| 1.14.14.94 | leukotriene B4 + [reduced NADPH-hemoprotein reductase] + O2 |
the enzyme plays a critical role in regulating the biological effect of leukotriene B4, CYP4F3 |
| 1.14.14.94 | leukotriene B4 + [reduced NADPH-hemoprotein reductase] + O2 |
induction of in all-trans-retinoic acid-treated HL60 cells |
| 1.14.14.94 | leukotriene B4 + [reduced NADPH-hemoprotein reductase] + O2 |
- |
| 1.14.14.94 | leukotriene B4 + [reduced NADPH-hemoprotein reductase] + O2 |
CYP4F3A is expressed in human leukocytes and catalyzes the omega-hydroxylation of LTB4 |
| 1.14.14.94 | more |
CYP4F3B and CYP4F2 may function collaboratively as 20-HETE synthetase as well as omega-hydroxylases for leukotiene b4 and other lipoxygenase-dependent eicosanoids in human liver and other tissues |
| 1.14.14.94 | more |
lipopolysaccharide treatament suppresses CYP4F4 and upregulates CYP4F5 mRNA expression in rat liver whereas renal CYP4Fs are essentially unchanged. BaSO4 treatment, in contrast, increases both hepatic and renal CYP4F expression levels |
